Protagenic Therapeutics appeals Nasdaq delisting; hearing set for Jan 30, 2025

Protagenic Therapeutics, Inc.new

Nasdaq determined non-compliance with $2.5M stockholders' equity requirement (Rule 5550(b)(1)).
Company failed to regain compliance by Nov 18, 2024 extension deadline; delisting determination issued Nov 19.
Appeal filed Nov 27; hearing stayed pending Panel decision; hearing scheduled Jan 30, 2025.
Materials due Jan 10, 2025; no assurance Panel will grant more time to regain compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.